Related Experiment Videos
Fingolimod. Mitsubishi Pharma/Novartis.
1Francisj_dumont@yahoo.com
Idrugs : the Investigational Drugs Journal
|March 18, 2005
Summary
Fingolimod, an oral immunosuppressant, is being developed to prevent organ transplant rejection and treat autoimmune conditions like multiple sclerosis by modulating lymphocyte circulation. It functions as a sphingosine-1-phosphate receptor agonist after in vivo phosphorylation.
Area of Science:
- Immunology
- Pharmacology
- Transplantation Medicine
Background:
- Fingolimod is an orally active immunosuppressant developed by Mitsubishi Pharma Corp and Novartis AG.
- It impacts lymphocyte re-circulation, a key process in immune responses.
- Potential applications include preventing transplant rejection and treating autoimmune diseases.
Purpose of the Study:
- To investigate the therapeutic potential of fingolimod.
- To understand its mechanism of action as an immunosuppressant.
Main Methods:
- Fingolimod is a synthetic sphingosine analog.
- It undergoes in vivo phosphorylation to its active form.
- The active metabolite acts as a sphingosine-1-phosphate receptor agonist.
Main Results:
- Fingolimod effectively modulates lymphocyte re-circulation.
- Demonstrates potential in preventing transplant rejection.
- Shows promise for treating autoimmune diseases such as multiple sclerosis.
Conclusions:
- Fingolimod's mechanism as a sphingosine-1-phosphate receptor agonist supports its immunosuppressive effects.
- It represents a promising therapeutic candidate for transplantation and autoimmune disorders.